IMCR vs SLS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
IMCR · Immunocore$30.99 ▲ 9.12%
SLS · Sellas Life Sciences$8.42 ▲ 6.85%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- IMCR -11.5%
- SLS +461.3%
Head to head
| Metric | IMCR | SLS |
|---|---|---|
| Price | $30.99 | $8.42 |
| Change today | ▲ 9.12% | ▲ 6.85% |
| Market cap | $1.60B | $1.70B |
| Return, 3 months | -8.8% | -23.7% |
| Return, year to date | -10.7% | +123.3% |
| Return, 1 year | -7.5% | +429.6% |
| P/E (TTM) | – | – |
| P/B | 3.8 | 12.3 |
| P/E percentile vs own 5y | 7th | 7th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +18.3% | – |
| Net profit growth (YoY) | +92.2% | -45.5% |
| Gross margin | 98.9% | – |
| Operating margin | -5.2% | – |
| Net margin | -4.2% | – |
| Return on equity | -4.5% | -39.6% |
| Analyst target vs. price | +94.3% | +256.3% |
| Analyst buy share | 67% | 100% |
| RSI (14) | 51 | 37 |
| 30-day volatility | 49.4% | 108.8% |
| Max drawdown, 1 year | -30.9% | -49.0% |
| Trend read | Leaning bearish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- SLS is the largest of the group by market value.
- SLS has returned the most over the past year.
- IMCR has been the calmest stock over the last 30 days.